Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Herpes Zoster (Shingles) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H2 2017, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape. Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 1, 1, 5, 1 and 1 respectively. Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Herpes Zoster (Shingles) - Overview Herpes Zoster (Shingles) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Herpes Zoster (Shingles) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development ContraVir Pharmaceuticals Inc Epiphany Biosciences Inc Foamix Pharmaceuticals Ltd GeneOne Life Science Inc GlaxoSmithKline Plc Merck & Co Inc NAL Pharmaceuticals Ltd NanoViricides Inc SK Chemicals Co Ltd XBiotech Inc Herpes Zoster (Shingles) - Drug Profiles acyclovir - Drug Profile Product Description Mechanism Of Action R&D Progress FV-100 - Drug Profile Product Description Mechanism Of Action R&D Progress GLS-5100 - Drug Profile Product Description Mechanism Of Action R&D Progress Herpes Zoster Vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress herpes zoster vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress herpes zoster vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody for Shingles - Drug Profile Product Description Mechanism Of Action R&D Progress NAL-3220 - Drug Profile Product Description Mechanism Of Action R&D Progress NBP-608 - Drug Profile Product Description Mechanism Of Action R&D Progress NN-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Shingles - Drug Profile Product Description Mechanism Of Action R&D Progress V-212 - Drug Profile Product Description Mechanism Of Action R&D Progress valomaciclovir stearate - Drug Profile Product Description Mechanism Of Action R&D Progress Herpes Zoster (Shingles) - Dormant Projects Herpes Zoster (Shingles) - Discontinued Products Herpes Zoster (Shingles) - Product Development Milestones Featured News & Press Releases Jul 10, 2017: NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin Jun 26, 2017: NanoViricides Poster Novel Nanoviricides Highly Effective Against Varicella Zoster Virus in Cell Culture to be Presented Today at the 2017 Annual Meeting of American Society of Virology Jun 21, 2017: GSK Presents Positive Results from Phase III Revaccination Study of its Candidate Shingles Vaccine Shingrix at CDC's Advisory Meeting Jun 21, 2017: Positive Phase 3 for GSK's Shingles Vaccine Shingrix with Agenus QS-21 Stimulon Immune Adjuvant Jun 06, 2017: NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies Apr 18, 2017: GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles Feb 24, 2017: In First Phase 3 Trial, Merck's Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects Nov 25, 2016: GSK announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada Oct 27, 2016: GSK presents new data for shingles candidate vaccine at IDWeek scientific conference Oct 24, 2016: GSK announces US regulatory submission of candidate vaccine for prevention of shingles Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study Oct 27, 2015: GSK's candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Herpes Zoster (Shingles), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017 Herpes Zoster (Shingles) - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017 Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences Inc, H2 2017 Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017 Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H2 2017 Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H2 2017 Herpes Zoster (Shingles) - Pipeline by Merck & Co Inc, H2 2017 Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H2 2017 Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H2 2017 Herpes Zoster (Shingles) - Pipeline by SK Chemicals Co Ltd, H2 2017 Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H2 2017 Herpes Zoster (Shingles) - Dormant Projects, H2 2017 Herpes Zoster (Shingles) - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
